-transparent.png){kind=logo}
A method has been developed for studying host-cell reactivation of cisplatin-damaged plasmid DNA in human T lymphocytes. Parameters of electroporation were established for transfection of the shuttle vector pRSV cat into H9 cells, and a rapid single-vial assay was used for measurement of chloramphenicol acetyltransferase (CAT) activity in extracts of transfected cells. pRSVcat was modified with cisplatin to defined levels ranging from 5 to 40 platinum molecules per plasmid, and then transfected into H9 cells. Graded reductions in CAT activity were observed with increasing levels of platination of the plasmid. At 40 platinum molecules per plasmid, CAT activity was reduced to levels of the negative controls. The efficiency of electroporation-mediated transfer of plasmid into H9 cells was not reduced by high levels of cisplatin modification. The level of modification effecting a 63% reduction in CAT gene expression (the B0), was found to be 17 cisplatin molecules per plasmid. This assay system offers a rapid and sensitive method for assessing the capability of human lymphoid cells to reactivate cisplatin-damaged plasmid DNA.
M Dabholkar, and
A Eastman, and
E Reed
April 1992,
Cancer letters,
M Dabholkar, and
A Eastman, and
E Reed
July 1990,
Biochemical and biophysical research communications,
M Dabholkar, and
A Eastman, and
E Reed
June 2013,
Oncology reports,
M Dabholkar, and
A Eastman, and
E Reed
November 1967,
Biochemical and biophysical research communications,
M Dabholkar, and
A Eastman, and
E Reed
January 1975,
Basic life sciences,
M Dabholkar, and
A Eastman, and
E Reed
June 1979,
Nature,
M Dabholkar, and
A Eastman, and
E Reed
January 1994,
Cancer investigation,
M Dabholkar, and
A Eastman, and
E Reed
October 1986,
Carcinogenesis,
M Dabholkar, and
A Eastman, and
E Reed
October 1977,
Cancer research,
M Dabholkar, and
A Eastman, and
E Reed
May 1999,
British journal of cancer,
